Current Report Filing (8-k)
21 Octobre 2022 - 10:06PM
Edgar (US Regulatory)
0000001800
false
Common Shares, Without Par Value
ABT
0000001800
2022-10-18
2022-10-18
0000001800
us-gaap:CommonStockMember
exch:XCHI
2022-10-18
2022-10-18
0000001800
us-gaap:CommonStockMember
exch:XNYS
2022-10-18
2022-10-18
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
Common Shares, Without Par Value |
|
ABT |
|
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D. C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the
Securities Exchange Act of 1934
October 18, 2022
Date of Report (Date of earliest event reported)
ABBOTT LABORATORIES
(Exact name of registrant as specified in
charter)
Illinois |
|
1-2189 |
|
36-0698440 |
(State or other Jurisdiction |
|
(Commission File Number) |
|
(IRS Employer |
of Incorporation) |
|
|
|
Identification No.) |
100 Abbott Park Road
Abbott Park, Illinois 60064-6400
(Address of principal executive offices)(Zip
Code)
Registrant’s telephone number, including
area code: (224) 667-6100
Check the appropriate box below if the Form 8-K filing
is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities Registered Pursuant to Section 12(b) of
the Act:
Title of Each Class |
Trading
Symbol(s) |
Name of Each Exchange
on
Which Registered |
Common
Shares, Without Par Value |
ABT |
New
York Stock Exchange
Chicago
Stock Exchange, Inc. |
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of
the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ¨
If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with
any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 5.02 | Departure of Directors or Certain Officers; Election of
Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers |
As previously reported, Abbott has Agreements Regarding Change in Control
(“Agreements”) with its named executive officers.
The Agreements provide that if Abbott gives notification of extension
before the Expiration Date (December 31, 2022), the Agreement’s term shall continue through the second anniversary of the Expiration
Date.
On October 18, 2022, Abbott notified the named executive officers that
the term of the Agreements was extended through December 31, 2024.
SIGNATURE
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
ABBOTT LABORATORIES |
|
|
|
Date: October 21, 2022 |
By: |
/s/ Robert E. Funck, Jr. |
|
|
Robert E. Funck, Jr. |
|
|
Executive Vice President, Finance and Chief Financial Officer |
Abbott Laboratories (NYSE:ABT)
Graphique Historique de l'Action
De Mar 2024 à Avr 2024
Abbott Laboratories (NYSE:ABT)
Graphique Historique de l'Action
De Avr 2023 à Avr 2024